Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TanCAR19/20 T Cells in R/R B-cell Malignancies
NCT03097770Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2017
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TanCAR19/20 in B-cell non-Hodgkin lymphoma, B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), sponsored by Chinese PLA General Hospital. Started Apr 2017; status: completed.
02
Drugs
TanCAR19/20
03
Conditions
B-cell non-Hodgkin lymphomaB cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03097770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097770.